Fenretinide
From Wikipedia, the free encyclopedia
| Fenretinide | |
|---|---|
 |
|
| IUPAC name | (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7- dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl) nona-2,4,6,8-tetraenamide |
| Identifiers | |
| CAS number | [65646-68-6] |
| PubChem | |
| MeSH | |
| Properties | |
| Molecular formula | C26H33NO2 |
| Molar mass | 391.546 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Fenretinide (INN) is a synthetic retinoid which are substances related to vitamin A. It has been investigated for potential use in the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, psoriasis, and has been found to also slow the production and accumulation of a toxin that leads to vision loss in Stargardt's patients.
In cancer studies, Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. Specific types of cancer under investigation include bladder, breast, Non-Hodgkin's lymphoma and neuroblastoma.
Numerous references and links to current and past clinical trials and studies of Fenretinide can be found at the Journal of Clinical Oncology website at http://jco.ascopubs.org/cgi/content/abstract/19/6/1664
[edit] References
- ^ Wu J, DiPietrantonio A, Hsieh T (2001). "Mechanism of fenretinide (4-HPR)-induced cell death". Apoptosis 6 (5): 377–88. doi:. PMID 11483862.
 |
This article about an organic compound is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
